(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
This can result in inadequate nutrient intake, muscle loss, fatigue, and micronutrient deficiencies
Leptin stimulates hepatic gluconeogenesis and hepatic insulin sensitivity via the hepatic branch of the vagus nerve
Do not try to warm it in any other way
Results vary by individual and depend on your dose, your health, and the diet and exercise changes you make
and a distributed network fanning out from the midbrain to the prefrontal cortex orchestrates reward elements